Study Evaluating Chemotherapy and Dual Immunotherapy Followed by Surgery in Adults with Inoperable Pleural Mesothelioma

What this Trial Is About

Researchers are evaluating whether combining chemotherapy and immunotherapy can make surgery possible for adults with inoperable pleural mesothelioma, a type of cancer affecting the lung lining. The study aims to find out if two cycles of neoadjuvant chemotherapy and dual immunotherapy followed by surgery can be completed safely and effectively, and if this approach can help patients previously considered inoperable become eligible for surgery and improve survival outcomes. Participants will receive two cycles of chemotherapy using either cisplatin or carboplatin combined with pemetrexed, along with dual immunotherapy consisting of nivolumab and ipilimumab. After these treatments, a multidisciplinary team will evaluate if surgery is possible. If deemed operable, participants will undergo an extended pleurectomydecortication surgery. This study includes a treatment phase followed by surgical intervention for those eligible. During the study, participants will be followed for one year to monitor side effects, quality of life, and survival. Researchers will assess the completion rate of the combined chemotherapy and immunotherapy regimen followed by surgery around week 17. Additional evaluations include treatment toxicity, surgery outcomes, operability after systemic treatment at weeks 7 to 9, and quality of life at week 17. Safety and effectiveness will be closely monitored throughout the study period.

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study